Caregiver Education on Alzheimer Agitation Is Essential: A Q&A with Geriatric Nurse Practitioner Carolyn Clevenger
Clevenger explains how better recognition of agitation in Alzheimer disease, and stronger caregiver–clinician communication, can meaningfully improve outcomes.
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
A multidisciplinary panel of neurologists, geriatricians, and researchers examined how early identification, equitable access, and value-based models could reshape Alzheimer disease care.
This Year in Primary Care: 10 Critical Updates in 2025
Stay informed with the latest critical updates, including new guidelines, vaccine insights, and groundbreaking research findings from 2025.
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
FDA Approves Abbott Volt Pulsed Field Ablation System for Treatment of Atrial Fibrillation
Abbott's Volt PFA System gains FDA approval, offering a new minimally invasive treatment for atrial fibrillation, enhancing patient care options.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
Colonoscopy May be the Gold Standard, But Now It's a CRC Screening Bottleneck, Says Mark Fendrick, MD
Completion of the screening pathway—not test selection alone—may define quality going forward.
When Daily Oral PrEP Is Not the Best Fit: Lessons From Clinical Practice
Real-world patient cases illustrating how pill burden, privacy, and individual preferences influence PrEP selection and adherence.
Moderate-to-Severe OSA Tied to Doubled Risk of Brain Microbleeds: Daily Dose
Your daily dose of the clinical news you may have missed.
Tezepelumab Achieves Dual Benefit in Adults with Severe Asthma: Daily Dose
FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH
Phase 3 LIBerate data showed sustained LDL-C reductions of 60% or more in high-risk patients and 50% or more in HeFH, with once-monthly self-administration.
How Long-Acting Injectable PrEP Reshapes the Patient–Provider Relationship
Primary care physician Kevin Hatfield, MD, discusses how the switch can increase patient touchpoints, free cognitive burden, and strengthen long-term engagement between patients and PCPs.
Noninvasive CRC Screening Needs More Primary Care Advocates: Thoughts from Mark Fendrick, MD
In CRC Screening, Progress Looks More Like Improved Follow-Through vs Next Breakthrough: Discussion with Mark Fendrick, MD
Moving patients from considering screening to completing it remains the central challenge in colorectal cancer prevention, Fendrick explained to Patient Care.
Zasocitinib Demonstrates Superiority vs Placebo and Apremilast in Phase 3 Plaque Psoriasis Trials
Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.
Novo Nordisk Files NDA for CagriSema, Novel GLP-1-amylin Combination for Chronic Weight Management
The phase 3 REDFINE program showed mean weight loss of 20% at 68 weeks, supporting the dual-mechanism approach that combines semaglutide with cagrilintide.
Hidradenitis Suppurativa: A Comprehensive Care Plan for Primary Care
This is a summary of the multisystem effects of hidradenitis suppurativa followed by practical tips for primary care in recognizing and managing the chronic skin condition.
GLP-1 RAs Carry Higher Risk of Serious GI Side Effects Than SGLT-2 Inhibitors: Daily Dose
Epicutaneous Immunotherapy Patch Reduces Peanut Reactivity in Children, Phase 3 Data Show
The VITESSE trial met its primary endpoint, with the VIASKIN Peanut patch improving desensitization versus placebo in peanut-allergic children aged 4 to 7 years.
Colorectal Cancer Screening in 2025: What Changed, and What Didn't, with Mark Fendrick, MD
Physician researcher Fendrick offers an expert perspective on why removing cost barriers matters, and why navigation and patient realities still determine whether CRC screening succeeds.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management")
